Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.65 |
| ▸ | SRC | P12931 | 2/20 | 0.65 |
| ▸ | BCR | P11274 | 7/20 | 0.63 |
| ▸ | BRAF | P15056 | 5/20 | 0.58 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.55 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.54 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.53 |
| ▸ | LDLR | P01130 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.53 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14731295 | 0.92 | ABL1 (0.57) | ABL1SRCBCRBRAFDDR1 | |
| SCHEMBL12433475 | 0.90 | ABL1 (0.63) | ABL1SRCBCRBRAFDDR1 | |
| SCHEMBL2314380 | 0.89 | ABL1 (0.72) | ABL1SRCBCRBRAFDDR1 | |
| SCHEMBL14717734 | 0.85 | ABL1 (0.57) | ABL1SRCBCRBRAFDDR1 | |
| SCHEMBL14110085 | 0.82 | ABL1 (0.56) | ABL1SRCBCRBRAFDDR1 | |
| SCHEMBL12432449 | 0.82 | CSF1R (0.58) | ABL1SRCBCRBRAFDDR1 | |
| SCHEMBL2311780 | 0.82 | ABL1 (0.62) | ABL1SRCBCRBRAF | |
| SCHEMBL14731314 | 0.82 | ABL1 (0.54) | ABL1SRCBCRBRAFDDR1 | |
| SCHEMBL14717859 | 0.82 | ABL1 (0.55) | ABL1SRCBCRBRAFDDR1 | |
| SCHEMBL14717736 | 0.80 | ABL1 (0.53) | ABL1SRCBCRBRAFDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | CDK2, TK1, DTYMK | ABL1 149/4885SRC 298/4885BCR 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.